Background illustration for clinical trials search

Paid Clinical Trials Allentown

Discover 2,147 paid clinical trials in Allentown, Pennsylvania. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2

Sacral Neuromodulation for Male Overactive Bladder (MOAB)

for
Overactive Bladder, Urinary Urgency Incontinence,
Location: Bala-Cynwyd PA, New York NY, Annapolis MD,
Sponsor: Axonics, Inc.

Sex: Male

Age: 18+

Code: NCT06511141

Recruiting

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

for
High-Risk Non-Muscle-Invasive Bladder Cancer
Location: Bala-Cynwyd PA, Philadelphia PA, Lancaster PA,
Sponsor: CG Oncology, Inc.

Sex: All

Age: 18+

Code: NCT06567743

Phase2, Recruiting

Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management

for
Prostate Cancer
Location: Bala-Cynwyd PA
Sponsor: MidLantic Urology

Sex: Male

Age: 18+

Code: NCT05799248

Phase3, Recruiting

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

for
Non-Muscle Invasive Bladder Cancer
Location: Bala-Cynwyd PA, New Brunswick NJ, Lancaster PA,
Sponsor: Janssen Research & Development, LLC

Sex: All

Age: 18+

Code: NCT06319820

Phase3, Recruiting

A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

for
Urinary Bladder Neoplasms,
Location: Bala-Cynwyd PA, New York NY, Virginia Beach VA,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06833073

Phase2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

for
Intermediate Risk Non-Muscle Invasive Bladder Cancer
Location: Bala-Cynwyd PA, Philadelphia PA, Morristown NJ,
Sponsor: Ferring Pharmaceuticals

Sex: All

Age: 18+

Code: NCT06510374

Phase3, Recruiting

Trial of Ureteroscopy vs Steerable Continuous Flow Aspiration Technology

for
Urolithiasis, Stones, Kidney, Renal Stones, Kidney Stones
Location: Bala-Cynwyd PA, New York NY, Birmingham AL,
Sponsor: Calyxo, Inc.

Sex: All

Age: 18+

Code: NCT07101809

Recruiting

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

for
NMIBC
Location: Cynwyd PA, Troy MI, Atlanta GA, Nashville TN,
Sponsor: ImmunityBio, Inc.

Sex: All

Age: 18 - 70+

Code: NCT06800963

Phase1, Phase2, Recruiting

PSMA PET Combined With MRI for the Detection of PCa

for
PCA, Prostate Cancer, Prostatic Neoplasm, PSMA PET,
Location: Philadelphia PA, New York NY, Virginia Beach VA,
Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited

Sex: Male

Age: 18+

Code: NCT07052214

Phase3, Recruiting

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

for
Non-Muscle Invasive Bladder Neoplasms
Location: Bala-Cynwyd PA, Lancaster PA, Voorhees Township NJ,
Sponsor: Janssen Research & Development, LLC

Sex: All

Age: 18+

Code: NCT06919965

Phase3, Recruiting

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

for
Metastatic Castration Sensitive Prostate Cancer (mCSPC),
Location: Bala-Cynwyd PA, Basking Ridge NJ, Lancaster PA,
Sponsor: Pfizer

Sex: Male

Age: 18+

Code: NCT07028853

Phase3, Recruiting

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

for
Metastatic Castration-resistant Prostatic Neoplasms
Location: Bala-Cynwyd PA, Philadelphia PA, Lancaster PA,
Sponsor: Janssen Research & Development, LLC

Sex: Male

Age: 18+

Code: NCT07164443

Phase3, Recruiting

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

for
Low-grade NMIBC, FGFR Gene Amplification, FGFR Gene Alterations,
Location: Bala-Cynwyd PA, Morristown NJ, Lancaster PA,
Sponsor: Tyra Biosciences, Inc

Sex: All

Age: 18+

Code: NCT06995677

Phase2, Recruiting

Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Location: Bala-Cynwyd PA, Lancaster PA, North Hills NY, Towson MD,
Sponsor: Dendreon

Sex: Male

Age: 18+

Code: NCT06134232

Phase2, Recruiting

Musculoskeletal Impairment in Headaches Attributed to Rhinosinusitis

for
Headache
Location: Havertown PA, Lafayette NJ, Totowa NJ, Hartford CT,
Sponsor: Des Moines University

Sex: All

Age: 18 - 65

Code: NCT04222244

Recruiting

Observational Registry to Assess the Durability of Effect of CXL in Patients With Corneal Ectasia After Refractive Surgery

for
Corneal Ectasia
Location: Bala-Cynwyd PA, McLean VA, Westerville OH, Ladson SC,
Sponsor: Glaukos Corporation

Sex: All

Age: 18+

Code: NCT03319082

Recruiting

Vancomycin Reduction Practices (VRP) in the NICU

for
Antibiotic Stewardship, Neonatal Sepsis, Late-Onset, Vancomycin
Location: West Chester PA, Philadelphia PA, Plainsboro NJ,
Sponsor: Children's Hospital of Philadelphia

Sex: All

Age: 18+

Code: NCT06772675

Recruiting

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

for
Solid Tumours
Location: Wynnewood PA, New York NY, Columbia MD, New Haven CT,
Sponsor: Boehringer Ingelheim

Sex: All

Age: 18+

Code: NCT06581432

Phase2, Recruiting

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)

for
Colon Cancer, Rectal Cancer, Colorectal Cancer,
Location: Wynnewood PA, Columbia MD, Norfolk VA, Salem VA,
Sponsor: SCRI Development Innovations, LLC

Sex: All

Age: 18+

Code: NCT07011576

Phase2, Recruiting

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Location: Broomall PA, Hackensack NJ, York PA, Fairfax VA,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06136559

Phase3, Recruiting